In Situ Hybridization Market Size to Reach USD 3.43 Billion by 2032 Owing to the Surging Incidence of Cancer and Genetic Diseases Globally | S&S Insider
The demand for advanced molecular diagnostic techniques, including the in situ hybridization (ISH) is being driven by the rising prevalence of genetic disorders and cancer.
Austin, Oct. 07, 2025 (GLOBE NEWSWIRE) — According to S&S Insider, the In Situ Hybridization Market was valued at USD 1.82 billion in 2023 and is expected to reach USD 3.43 billion by 2032, growing at a CAGR of 7.33% over 2024-2032.
Technological Advancements in ISH Techniques is Boosting Market Growth Globally
The market is expanding due to significant technological advancements in in situ hybridization techniques, particularly chromogenic in situ hybridization (CISH) and fluorescence in situ hybridization (FISH). Assay sensitivity, specificity, and workflow efficiency have increased thanks to developments, such as RNA-based ISH, multiplexing capabilities, and automated hybridization platforms.
Get free Sample Report of In Situ Hybridization Market: https://www.snsinsider.com/sample-request/5762
Automated ISH solutions are perfect for high-throughput research and clinical labs because they reduce human error and improve reliability. ISH automation was revolutionized in January 2024, when Biocare Medical and Molecular Instruments teamed up to integrate automated bioimaging equipment with hybridization chain reaction technology. These developments have the potential to increase the use of ISH in clinical diagnostics, academic research, and the pharmaceutical industry for the early detection of genetic disorders, cancer, and infectious diseases while improving overall diagnostic efficiency and accuracy.
Major Players Analysis Listed in the In Situ Hybridization Market Report are
- Agilent Technologies Inc.
- F. Hoffmann-La Roche Ltd.
- Thermo Fisher Scientific Inc.
- BioGenex Laboratories
- Abnova Corporation
- Biocare Medical LLC.
- Genemed Biotechnologies Inc.
- Zytomed Systems GmbH
- Creative Bioarray
- Bio SB Inc.
- Abbott Laboratories
- Danaher Corporation
- Bio-Techne Corporation
- Oxford Gene Technology
- PerkinElmer Inc.
- Merck KGaA
- Advanced Cell Diagnostics Inc.
- Exiqon A/S
- Molecular Instruments Inc.
- ACD – A Bio-Techne Brand
In Situ Hybridization Market Report Scope
| Report Attributes | Details |
| Market Size in 2023 | US$ 1.82 Billion |
| Market Size by 2032 | US$ 3.43 Billion |
| CAGR | CAGR of 7.33% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Regional Analysis | North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) |
| Key Growth Drivers | The growing prevalence of cancer and genetic disorders is driving the demand for advanced molecular diagnostic techniques such as in situ hybridization (ISH). |
Segmentation Analysis:
By Technology
The Fluorescence In Situ Hybridization (FISH) segment dominated the In Situ Hybridization (ISH) market in 2023 with a 54.25% market share, owing to its sensitivity, specificity, and extensive usage in cancer diagnostics and genetic studies. The Chromogenic In Situ Hybridization (CISH) segment is expected to grow at the fastest rate during the forecast period with 7.71% CAGR as it is cost-effective, easy to interpret under a standard brightfield microscope, and increasingly preferred in resource-constrained environments.
By Probe
The DNA probe segment dominated the market with 58.41% market share in 2023, as it finds wide applications in cancer diagnosis, detection of genetic disorders, and chromosomal studies. The RNA probe segment is anticipated to grow at the fastest rate during the forecast years with the growing need for gene expression analysis, infectious disease diagnosis, and neuroscience research.
By Product
The Instruments segment dominated the in situ hybridization (ISH) market with a 34.12% market share in 2023 owing to the growing adoption of automated ISH platforms that improve efficiency, accuracy, and reproducibility in diagnostic and research laboratories.
By Application
The Cancer segment dominated the market with a 41.26% market share in 2023 on account of the growing cancer incidence and the escalating usage of molecular diagnostic methods for early diagnosis and targeted therapy globally.
By End-use
The Hospitals & Diagnostic Laboratories segment dominated the in situ hybridization (ISH) market with a 48.32% market share in 2023 owing to the growing need for precise and early disease diagnosis, especially in cancer and genetic disorders. The CROs (Contract Research Organizations) segment is expected to grow the fastest during the forecast period due to the trend of outsourcing in drug discovery and biomarker research.
In Situ Hybridization Market Key Segments
By Technology
- FISH
- CISH
- By Probe
- DNA
- RNA
By Product
- Instruments
- Consumables & Accessories
- Software
- Services
By Application
- Cancer
- Cytogenetics
- Developmental Biology
- Infectious Diseases
- Others
By End-use
- Hospitals & Diagnostic Laboratories
- CROs
- Academic & Research Institutes
- Others
Buy the In Situ Hybridization Market Report Now: https://www.snsinsider.com/checkout/5762
North America Held the Largest Market Share of 45.25% in 2023; Asia Pacific is Expected to Grow with the Fastest CAGR of 8.43% Over 2025-2032
North America dominated the in situ hybridization (ISH) market with a 45.25% market share in 2023, due to its well-developed healthcare system, high density of major industry players, and strong adoption of molecular diagnostic methods. Asia Pacific is the fastest growing region throughout the forecast period with 8.43% CAGR, driven by growing healthcare investments, rising incidence of genetic diseases, and developing biotech and pharma sectors.
Recent News:
- In January 2024, Akoya Biosciences signed a license and distribution deal with Thermo Fisher Scientific. Under this partnership, Akoya is permitted to distribute its spatial biology solutions, which include imaging systems and reagents, in conjunction with Thermo Fisher’s in situ hybridization assays. Through the partnership, the detection of protein and RNA biomarkers within tissue samples will be improved, enhancing research and diagnostics in spatial biology.
- In January 2024, Biocare Medical revealed a partnership with Molecular Instruments to boost the automation of in situ hybridization and immunohistochemistry. Through the combination of Biocare Medical’s experience in automated bioimaging systems and Molecular Instruments’ hybridization chain reaction technology, the partnership aims to establish new benchmarks in automated biomarker detection.
Exclusive Sections of the Report (The USPs):
- INCIDENCE & PREVALENCE METRICS – helps you understand the disease burden and diagnostic demand drivers shaping ISH test adoption across key therapeutic areas.
- ADOPTION TRENDS BY REGION – helps you identify markets with varying levels of ISH technology uptake, guiding regional expansion and localization strategies.
- ISH TEST VOLUME FORECAST (2020–2032) – helps you track procedural growth and market scalability, providing insights into long-term demand trends across regions.
- RESEARCH & CLINICAL SPENDING LANDSCAPE – helps you evaluate funding distribution across government, commercial, private, and out-of-pocket segments to gauge investment potential.
- REGIONAL MARKET OPPORTUNITY INDEX – helps you pinpoint high-growth geographies by integrating epidemiological trends, test volumes, and spending data for strategic decision-making.
Access Complete Report Details of In Situ Hybridization Market Analysis & Outlook: https://www.snsinsider.com/reports/in-situ-hybridization-market-5762
[For more information or need any customization research mail us at info@snsinsider.com]
About Us:
S&S Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company’s aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
CONTACT: Contact Us: Rohan Jadhav - Principal Consultant Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK) Email: info@snsinsider.com
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. IndiaShorts takes no editorial responsibility for the same.